Study in NSCLC: is Timely Analysis of EGFR-mutation Status Feasible in Region Antwerp, Belgium.

Retrospective Study in a NSCLC M+ p

NCT01795352 ·Status: COMPLETED

GIOTRIF in First Line Therapy of Advanced NSCLC With EGFR-mutations

NCT02047903 ·Status: COMPLETED

Implementing Circulating Tumor DNA Analysis at Initial Diagnosis to Improve Management of Advanced NSCLC Patients

NCT04912687 ·Status: COMPLETED ·Phase: NA

Retrospective Study in Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR)

NCT02293733 ·Status: COMPLETED

A Study of Prevalence of EGFR Mutations in Participants With NSCLC

NCT02695849 ·Status: COMPLETED

Resistance & Activating Mutations Diagnosed Among NSCLC Community Dwelling EGFR Mutation Positive Patients

NCT03137264 ·Status: COMPLETED

Erlotinib Treatment Beyond Progression in EGFR Mutant NSCLC

NCT02064491 ·Status: COMPLETED ·Phase: PHASE2

Diagnosis and Treatment Strategies in Patients With NSCLC With or Without EGFR Mutations.

NCT01525199 ·Status: COMPLETED

A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting

NCT07230691 ·Status: RECRUITING

Afatinib in NSCLC With HER2 Mutation

NCT02369484 ·Status: COMPLETED ·Phase: PHASE2

Overcoming Resistance to EGFR Neutralization by Combination of Monoclonal Antibodies and Novel Cancer Drugs

NCT06863818 ·Status: ACTIVE_NOT_RECRUITING

Afatinib in Patients With Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Mutations

NCT02044380 ·Status: COMPLETED ·Phase: PHASE3

Expanded Access Study of Afatinib in Treatment-naive or Chemotherapy Pre-treated Patients With Non-small Cell Lung Cancer (NSCLC)

NCT01931306 ·Status: APPROVED_FOR_MARKETING

Frequency of EGFR Mutations in Latinos/Hispanics With Non-Small Cell Lung Cancer

NCT01255150 ·Status: COMPLETED

Iressa Re-challenge in Advanced NSCLC EGFR-mutated Patients

NCT02025218 ·Status: TERMINATED ·Phase: PHASE2

Non-interventional, Prospective Study to Determine Prevalence of EGFR Mutations in Non-small Cell Lung Cancer

NCT04742192 ·Status: COMPLETED

A Non-interventional Survey on the EGFR (Epidermal Growth Factor Receptor) Mutation Status in Completely Resected Chinese Non-Small Cell Lung Cancer (NSCLC) Patients With Adenocarcinoma Histology

NCT01106781 ·Status: COMPLETED

A Study to Assess the Incidence of EGFR Mutation in Patients With Newly Diagnosed Locally Advanced or Metastatic Non-Small Cell Lung Cancer in the UK, And of Tarceva (Erlotinib) as First-Line Therapy in EGFR Mutation Positive Patients.

NCT01250119 ·Status: COMPLETED ·Phase: PHASE2

Epidemiological and Scientific Evaluation of EGFR Mutation Status in Patients With Newly Diagnosed Locally Advanced or m

NCT00997230 ·Status: COMPLETED

Pathomolecular Analysis of Rare EGFR Mutations in Advanced NSCLC

NCT01215474 ·Status: COMPLETED

The Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients With Advanced EGFR Mutation-positive Non-small Cell Lung Cancer Treated With Afatinib

NCT04640870 ·Status: COMPLETED

Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping

NCT04318938 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Study to Evaluate Concordance of Detecting EGFR (Epidermal Growth Factor Receptor) Mutation by Circulating Tumour Free DNA Versus Tissues Biopsy in NSCLC (Non-small Cell Lung Cancer).

NCT03562819 ·Status: COMPLETED

A Multicenter Randomized Phase III Study Comparing Second-line Treatment With Chemotherapy Associated or Not to Erlotinib in NSCLC Patients With Secondary Resistance to TKI-EGFR

NCT02178397 ·Status: TERMINATED ·Phase: PHASE3

Afatinib in Lung Cancer With EGFR Mutation From Circulating Tumor DNA

NCT02629523 ·Status: COMPLETED ·Phase: PHASE2